Forge Therapeutics and Evotec have launched a discovery platform to develop novel antibiotics targeting metalloenzymes.
Around a third of Trevena’s workforce are facing the ax as the biotech throws all its weight behind soon-to-be-filed injectable pain therapy Olinvo.
The complex and intertwined dual epidemics of poorly treated pain and opioid addiction require a combined, artful approach to secure the best possible results…
Just months after its $80 million IPO, AnaptysBio is looking to raise another block of cash and accelerate development of its lead drug for eczema.
French biotech Biophytis has raised the funds it needs to start midstage trials of two drugs for age-related diseases via a private placement.
Rhythm Pharmaceuticals has topped its expectations in its IPO, selling more shares—at a higher price—than expected when it announced its intention to go public…
Intra-Cellular Therapies raised its target of $150 million, which will help it prepare for an FDA filing for lumateperone in schizophrenia next year.
U.K. biotech NeRRe Therapeutics has decided to streamline its R&D portfolio by setting up a brand-new company focusing on women’s health.
Alexion is slashing its workforce by around 20% and closing sites in a bid to save $250 million a year, with R&D bearing the brunt.
The stock exchange has given Auris until Oct. 2 to meet the stockholders’ equity requirement.
Canadian investment group TRC Capital—well known for its min-tender offer strategy—has now set its sights on Ionis, and the biotech group is not happy.